None listed
Conditions
Interventions
In this study, markers of growth hormone (GH) doping will be measured in healthy volunteers in response to administration of GH and/or testosterone. Healthy male and female recreationally trained athletes will be randomised to growth hormone/placebo. The duration of intervention with GH is for 8 weeks in total. For the first 3 weeks, the dose of GH will be increased in a step-wise manner then maintained at the final dose for 5 weeks. Males will also be treated with testosterone/placebo for the l
In this study, markers of growth hormone (GH) doping will be measured in healthy volunteers in response to administration of GH and/or testosterone. Healthy male and female recreationally trained athletes will be randomised to growth hormone/placebo. The duration of intervention with GH is for 8 weeks in total. For the first 3 weeks, the dose of GH will be increased in a step-wise manner then maintained at the final dose for 5 weeks. Males will also be treated with testosterone/placebo for the last 5 weeks, in addition to GH/placebo. After the treatment period there will be further 6 weeks follow up.
Sponsors
St Vincent's Hospital Sydney Ltd
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Diagnosis
Masking
Blinded (masking used)
Eligibility
Sex/Gender
All
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
1. Regular participation in at least 2 exercise sessions/week for at least 1 year.
Exclusion criteria
1. Athletes who participate in competition at the state or national level or higher 2. Subjects who have taken any performance-enhancing drug previously (assessed by self reporting) 3. Pregnancy 4. Diabetes mellitus 5. History of cardiovascular, hepatic or renal disease 6. Known cancer.
Outcome results
None listed